Stroke is the leading cause of disability in the US and is a major global health problem. It has been identified as one of the largest causes of lost productivity in late adulthood. The multiple life-altering complications that result from stroke-such as paresis, mood disorders, aphasia, cognitive deficits, dysarthria, dysphagia, and visual disturbances-may be confounded by the development of spasticity. Upper-limb spasticity can be particularly debilitating.
Objectives
This article focuses on post-stroke upper-extremity spasticity. A descriptive examination of the relevant literature was performed with the objectives of: examining the efficacy of BTX-A injection in post-stroke upper-extremity spasticity; investigating whether or not reduction of spasticity translates
into improvement in quality of life for patients and/or care-givers; and evaluating functional improvement in the upper extremities after injection.
We have also considered the literature with regard to safety after the use of BTX-A for upper-extremity spasticity due to stroke.
Methods
The literature used for this article was obtained after conducting a 
Results

Spasticity Scales
In the literature reviewed, the measurement scales used to grade spasticity are the Ashworth scale (AS) and Modified Ashworth scale (MAS) (see Table 1 ), and the Functional Independence Measure (FIM™) instrument. [2] [3] [4] [5] [6] [7] 9, [11] [12] [13] [14] [15] Of the reviewed studies, results showed statistical significance of improving spasticity in the muscles injected with BTX-A.
This was evidenced by decreased MAS scores measured at the elbow, wrist, fingers, and shoulder. [2] [3] [4] [5] [6] [7] [11] [12] [13] [14] [15] These findings were noted at multiple time periods after injection. The duration of the positive effect was seen to last for anywhere between 10 and 20 weeks, at which point re-injection was recommended. In one study, the improvement in MAS score and increase in range of motion was sustained until the 32nd week. 2 It has been suggested that there are larger improvements of spasticity in individuals who have retained some movement after stroke. 12 
Recurring Injections
Commonly, patients who need recurrent injections will receive them no more frequently than every three months, as it is thought that injecting more frequently than this may potentiate the development of antibodies to the toxin. This hypothesis has not yet been borne out in studies. In a study conducted by Bakheit et al., 5 they found no BTX-A antibodies detected from blood sample BTX-A antibody assays taken at baseline and on completion of the study, which was 12 weeks after the third treatment cycle of BTX-A.
Spasticity Reduction
The reduction of spasticity has been clearly defined in multiple studies. This change can translate into improvement in the QoL and/or functional improvement of patients. Upon review of the literature, there are both positive and negative findings with regard to this topic. One of the articles cited here is a meta-analysis reviewing 11 articles. In it, the Global Assessment Scale (GAS) was used as the objective measure for the perception of patient or care-givers of their QoL. A clinically significant improvement in GAS at four to six weeks after injecting BTX-A was found.
Despite the fact that BTX-A injections reduced excessive muscle tone in the elbow, wrist, and fingers, with sustained benefit occurring when injections were repeated after 12 weeks, there was no observed improvement in the QoL as measured on the Short Form Health Survey (SF-36) in studied subjects. 
Botox Treatment for Spasticity
A statistical analysis was performed of data from nine double-blind, placebo-controlled studies that included 482 patients with upper-limb spasticity. 10 These patients blindly received either BTX-A or placebo.
Adverse events were reported by the patient or the monitoring clinician.
Findings revealed that the majority of adverse events were rated as mild or moderate in severity and that nausea was the only event reported at a significantly higher rate in the BTX-A group than in the placebo group.
Aside from this study, there have been reports of flu-like symptoms expressed by patients after injection. None of the studies reviewed reported serious adverse events found to be directly related to administration of BTX-A. A recent pilot study suggests that some degree of strength and active movement is necessary for the action of BTX-A on intrafusal fibres. 
Summary
BTX-A is an efficacious treatment for upper-extremity spasticity after stroke. There exists an abundance of evidence from well-designed studies that exhibit the reduction of spasticity after BTX-A injection in the upper extremity. Although there continues to be a lack of consensus, the QoL for patients and care-givers is improved, likely given the fact that pain, hygiene, care-giver burden, and mobility are severely affected by spasticity.
Functional improvements after injection have also been noted, mostly seen in measures that directly evaluate function in the extremity rather than global assessments of function. BTX-A has been found to be a safe Botulinum Toxin Type A and Post-stroke Spasticity of the Upper Limbs 39 treatment causing reporting of mild to moderate side effects, if any at all.
Treatment with BTX-A may also obviate the need for other spasticity management options described above that may be contraindicated or cause further problems in patients.
Discussion
There are numerous issues that make research for treatment of neurological rehabilitation patients difficult. Among them is the debate surrounding measurement tools. The AS and MAS remain the most commonly used clinical scales in the measurement of spasticity. 9 Differences in training of examiners and the variability of spasticity with position, stress, temperature, illness, etc. make it very difficult to achieve standardized measurements. The variability of QoL results of these reviewed studies and others like them continue to drive the debate. QoL is a patient-and/or care-giver-specific issue. For example, patients have described perceived improvement in their physical appearance that may correlate with improved quality of life; however, it is extremely difficult to measure such a subjective point. For this reason, QoL measures will likely always be difficult to objectify. There exists great debate as to the actual functional improvements that can be achieved in patients with severe spasticity and differing degrees of paresis after BTX-A injections. Research has focused on using advanced techniques to improve injection accuracy such as electromyographic guidance (EMG) and electrical stimulation (ES)
in patients who are unresponsive or sedated. 17 Improvements seen in function in the above studies cannot be generalized to all stroke patients.
More studies are needed with narrowly selected patient populations in order to provide further guidelines for treatment in specific patient populations. It should also be noted that upper-extremity function can be more important than lower-limb function for independent living and selfesteem. 18, 19 Additionally, there is no established standard approach to the administration of BTX-A. The dosing regimen, targeted muscle groups, and practice of administration vary with the clinical presentation of patients, as do the approach of the individual injecting the drug and goals of injections. The extent of denervation is determined largely by the dose and volume of the injection given. 11, 16 Studies are available that demonstrate greater clinical improvement, fewer BTX-A-related side effects due to injection of the adequate dose of BTX-A to the accurate site of hyperactive muscles, and greater clinical improvement due to confirmation of hyperactivity of muscles with the use of EMG-guided injections. 20 Administration of BTX-A is often performed blindly and the procedure is not always well described in studies. These differences and others contribute to accounts of outcomes. This is compounded by the unresolved problem with measuring spasticity. 
